Cat.No. HYB 147-06
Mouse monoclonal antibody
HYB 147-06 is specific for the amidated C-terminus of the peptide and does not react with GLP-1(7-37) (1).
Synthetic GLP-1(7-36)amide coupled to carrier
C-terminal epitope of GLP-1(7-36)amide
Available in 200 µL and 1 mL size.1 mg/mL +/- 15%. See Certificate of Analysis for details.
Glucagon-like peptide 1(7-36)amide (GLP-1(7-36)amide) is the principal active form of GLP-1, the other being GLP-1(7-37). GLP-1 is a peptide hormone of the glucagon family, produced by the L cells of the intestinal mucosa from the same prohormone as glucagon. The active forms are potent stimulators of glucose-dependent insulin secretion. The sequence of GLP-1 is fully conserved in all mammalian species examined so far.
|This uses HYB 147-06 as capture antibody in combination with biotinylated detection antibody HYB 147-12 to measure the sum of GLP-1(7-36)amide, GLP-1(1-36)amide and GLP-1(9-36)amide in biological samples. Relative to measuring the two active forms of GLP-1, the responses are reduced by not measuring the contribution of GLP-1(7- 37) to the overall response, but this is compensated for by measuring an approximately equal contribution from GLP-1(1-36)amide. However, the GLP-1(9-36)amide degradation product is also measured, augmenting the response above that of the active forms alone. This assay cannot detect changes in active GLP-1 in response to treatment with DPP-4 inhibitors, and is therefore only suitable for experiments in which changes in GLP-1 degradation are irrelevant.|
|This uses HYB 147-06 as capture antibody in combination with biotinylated detection antibody ABS 033-10 exclusively to measure GLP-1(7-36)amide in biological samples. GLP-1(7-36)amide is the principal active form of the peptide, and has been estimated to make up about 70% of the physiological response. Relative to measuring both active forms of GLP-1 together, the responses are reduced by not measuring the approximately 30% contribution of GLP-1(7-37) to the overall response. There is no cross-reactivity with any extended or truncated physiological form of GLP-1(7-36)amide. Specimens must be collected into tubes containing an adequate amount of DPP-4 inhibitor (in addition to routine peptidase inhibitors) to prevent the rapid in vitro degradation of the active peptide.|
|The calibration curve of a sandwich assay for measuring degraded GLP-1 using ABS 044-49 as the capture antibody and HYB 147-06B as the biotinylated detection antibody.|
|Pancreas sections from diabetic mice stained with HYB 147-06 (1:500). Courtesy of Dr. Annette Plesner, University of British Columbia|
1. Ghiglione M, Uttenthal LO, Koch C (1993) Monoclonal antibodies to glucagon-like peptide-1. Digestion 54:396-397.
3. Piotrowski K, Becker M, Zugwurst J, Biller-Friedmann I, Spoettl G, Greif M, Leber AW, Becker A, Laubender RP, Lebherz C, Goeke B, Marx N, Parhofer KG, Lehrke M (2013) Circulating concentrations of GLP-1 are associated with coronary atherosclerosis in humans. Cardiovascular Diabetology 12:117.
4. Voortman T, Hendriks HFJ, Witkamp RF, Wortelboer HM (2012) Effects of long- and short-chain fatty acids on the relase of gastrointestinal hormones using an ex vivo porcine intestinal tissue model. J. Agric. Food Chem. 60:9035-9042.